Cargando…
Use of Pharmacokinetic Modeling to Design Studies for Pathway-Specific Exposure Model Evaluation
Validating an exposure pathway model is difficult because the biomarker, which is often used to evaluate the model prediction, is an integrated measure for exposures from all the exposure routes and pathways. The purpose of this article is to demonstrate a method to use pharmacokinetic (PK) modeling...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
National Institute of Environmental Health Science
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1253662/ https://www.ncbi.nlm.nih.gov/pubmed/15579416 http://dx.doi.org/10.1289/ehp.6367 |
_version_ | 1782125751259103232 |
---|---|
author | Hu, Ye Akland, Gerry G. Pellizzari, Edo D. Berry, Maurice R. Melnyk, Lisa Jo |
author_facet | Hu, Ye Akland, Gerry G. Pellizzari, Edo D. Berry, Maurice R. Melnyk, Lisa Jo |
author_sort | Hu, Ye |
collection | PubMed |
description | Validating an exposure pathway model is difficult because the biomarker, which is often used to evaluate the model prediction, is an integrated measure for exposures from all the exposure routes and pathways. The purpose of this article is to demonstrate a method to use pharmacokinetic (PK) modeling and computer simulation to guide the design of field studies to validate pathway models. The children’s dietary intake model is discussed in detail as an example. Three important aspects are identified for a successful design to evaluate the children’s dietary intake model: a) longitudinally designed study with significant changes in the exposure for the route/pathway of interest, b) short biologic half-life of the selected chemical, and c) surface loading of the selected chemical at sufficient levels. Using PK modeling to guide a study design allowed a path-specific exposure model to be evaluated using urinary metabolite biomarkers. |
format | Text |
id | pubmed-1253662 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | National Institute of Environmental Health Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-12536622005-11-08 Use of Pharmacokinetic Modeling to Design Studies for Pathway-Specific Exposure Model Evaluation Hu, Ye Akland, Gerry G. Pellizzari, Edo D. Berry, Maurice R. Melnyk, Lisa Jo Environ Health Perspect Research Validating an exposure pathway model is difficult because the biomarker, which is often used to evaluate the model prediction, is an integrated measure for exposures from all the exposure routes and pathways. The purpose of this article is to demonstrate a method to use pharmacokinetic (PK) modeling and computer simulation to guide the design of field studies to validate pathway models. The children’s dietary intake model is discussed in detail as an example. Three important aspects are identified for a successful design to evaluate the children’s dietary intake model: a) longitudinally designed study with significant changes in the exposure for the route/pathway of interest, b) short biologic half-life of the selected chemical, and c) surface loading of the selected chemical at sufficient levels. Using PK modeling to guide a study design allowed a path-specific exposure model to be evaluated using urinary metabolite biomarkers. National Institute of Environmental Health Science 2004-12 2004-08-16 /pmc/articles/PMC1253662/ /pubmed/15579416 http://dx.doi.org/10.1289/ehp.6367 Text en http://creativecommons.org/publicdomain/mark/1.0/ Publication of EHP lies in the public domain and is therefore without copyright. All text from EHP may be reprinted freely. Use of materials published in EHP should be acknowledged (for example, ?Reproduced with permission from Environmental Health Perspectives?); pertinent reference information should be provided for the article from which the material was reproduced. Articles from EHP, especially the News section, may contain photographs or illustrations copyrighted by other commercial organizations or individuals that may not be used without obtaining prior approval from the holder of the copyright. |
spellingShingle | Research Hu, Ye Akland, Gerry G. Pellizzari, Edo D. Berry, Maurice R. Melnyk, Lisa Jo Use of Pharmacokinetic Modeling to Design Studies for Pathway-Specific Exposure Model Evaluation |
title | Use of Pharmacokinetic Modeling to Design Studies for Pathway-Specific Exposure Model Evaluation |
title_full | Use of Pharmacokinetic Modeling to Design Studies for Pathway-Specific Exposure Model Evaluation |
title_fullStr | Use of Pharmacokinetic Modeling to Design Studies for Pathway-Specific Exposure Model Evaluation |
title_full_unstemmed | Use of Pharmacokinetic Modeling to Design Studies for Pathway-Specific Exposure Model Evaluation |
title_short | Use of Pharmacokinetic Modeling to Design Studies for Pathway-Specific Exposure Model Evaluation |
title_sort | use of pharmacokinetic modeling to design studies for pathway-specific exposure model evaluation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1253662/ https://www.ncbi.nlm.nih.gov/pubmed/15579416 http://dx.doi.org/10.1289/ehp.6367 |
work_keys_str_mv | AT huye useofpharmacokineticmodelingtodesignstudiesforpathwayspecificexposuremodelevaluation AT aklandgerryg useofpharmacokineticmodelingtodesignstudiesforpathwayspecificexposuremodelevaluation AT pellizzariedod useofpharmacokineticmodelingtodesignstudiesforpathwayspecificexposuremodelevaluation AT berrymauricer useofpharmacokineticmodelingtodesignstudiesforpathwayspecificexposuremodelevaluation AT melnyklisajo useofpharmacokineticmodelingtodesignstudiesforpathwayspecificexposuremodelevaluation |